Medical College of Wisconsin: Leukemia, Myeloid, Acute trials

The registry lists 15 Leukemia, Myeloid, Acute studies with Medical College of Wisconsin as lead sponsor. 2 are open to participants now and 9 have results posted.

Phase 1 5Phase 2 5Phase 3 4Phase 4 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Pragmatic Clinical Trial to Prevent Relapse for Myeloid Malignancies With Measurable Disease Prior to Allogeneic TransplantNot yet recruitingNCT07572929Phase 2
• Venetoclax to Augment Epigenetic Modification and ChemotherapyRecruitingNCT05317403Phase 1
• Patients Receiving Induction With Liposomal Daunorubicin and Cytarabine (CPX-351) for Acute Myeloid LeukemiaTerminatedNCT03988205Phase 4Results posted
• Efficacy and Pharmacogenomics of Cladribine Based Salvage Chemotherapy in Patients With Relapse/Refractory and Secondary Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)TerminatedNCT03150004Phase 2Results posted
• Double Cord Versus Haploidentical (BMT CTN 1101)CompletedNCT01597778Phase 3Results posted
• Reduced Intensity Regimen vs Myeloablative Regimen for Myeloid Leukemia or Myelodysplastic Syndrome (BMT CTN 0901)TerminatedNCT01339910Phase 3Results posted
• Hematopoietic Stem Cell Transplantation (HSCT) Using CD34 Selected Mismatched Related Donor and One Umbilical Cord UnitTerminatedNCT01050946Phase 2Results posted
• Evaluating the Safety and Effectiveness of an Umbilical Cord Blood Stem Cell Transplant (BMT CTN 0604)CompletedNCT00864227Phase 2Results posted
• Bone Marrow Transplant From Partially Matched Donors and Nonmyeloablative Conditioning for Blood Cancers (BMT CTN 0603)CompletedNCT00849147Phase 2Results posted
• Single vs Double Umbilical Cord Blood Transplants in Children With High Risk Leukemia and Myelodysplasia (BMT CTN 0501)CompletedNCT00412360Phase 3Results posted
• Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) (BMT CTN 0402)CompletedNCT00406393Phase 3Results posted
• Venetoclax-Navitoclax With Cladribine-based Salvage Therapy in Patients With Relapsed/Refractory Acute Myeloid LeukemiaWithdrawnNCT06007911Phase 1
• Pevonedistat, Azacitidine (or Decitabine), and Venetoclax for the Treatment of Patients With Acute Myelogenous LeukemiaTerminatedNCT04172844Phase 1
• Pracinostat and Gemtuzumab Ozogamicin (PraGO) in Patients With Relapsed/Refractory Acute Myeloid LeukemiaCompletedNCT03848754Phase 1
• Lintuzumab-Ac225 in Combination with Cladribine + Cytarabine + Filgastrim + Mitoxantrone (CLAG-M) for Relapsed/Refractory Acute Myeloid LeukemiaCompletedNCT03441048Phase 1